Melanoma And Skin Cancer Trials Limited
Clinical trials sponsored by Melanoma And Skin Cancer Trials Limited, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo therapy aims to halt merkel cell cancer spread Results expected Dec 2026 (estimated)
- Immunotherapy drug aims to stop rare skin cancer's return Results expected Apr 2027 (estimated)
-
Immunotherapy drug aims to stop rare skin cancer's return
Disease control OngoingThis study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…
Phase 2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo therapy aims to halt merkel cell cancer spread
Disease control OngoingThis study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…
Phase 1/2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Transplant patients get new hope: sirolimus cream may stop facial cancers
Disease control OngoingThis phase 3 trial tests whether a cream containing sirolimus (rapamycin) can prevent facial skin cancers in people who have received an organ transplant. 146 participants apply the cream or a placebo to their face every night for 6 months. The study counts new skin cancers durin…
Phase 3 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 26, 2026 15:07 UTC